← Back to Analyst Consensus 
EPRX Buy
EUPRAXIA PHARMACEUTICALS INC.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 1, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 24, 2026 | Wedbush | initiate | — → Outperform | — | 58% |
| Jun 26, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| May 21, 2026 | Stifel | initiate | — → Buy | — | 53% |
| May 4, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 22, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 23, 2026 | William Blair | initiate | — → Outperform | — | 48% |
| Mar 17, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jan 15, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | $19 | 50% |
| Jan 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| Aug 20, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| Jul 24, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $11 | 50% |
| Jun 26, 2025 | HC Wainwright & Co. | initiate | — → Buy | $12 | 44% |
| Nov 14, 2024 | Rodman & Renshaw | initiate | — → Buy | $9 | 40% |
Price Target Trend
Apr 23, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days